Panobinostat (LBH589)

For research use only.

Catalog No.S1030 Synonyms: NVP-LBH589

236 publications

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 117 In stock
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Panobinostat (LBH589) has been cited by 236 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 M3XYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnWeG1GOC1zMDFOwG0> NUj6U5Q5OC12IHS= MkDWbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUfhTnB2OjZ5MEK3PFQ>
HepG2 M4TTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7hPHExNTFyIN88US=> NV;tR2h2OC12IHS= Mn;SbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MUmyOlcxOjd6NB?=
HT29 NUH2V4VOTnWwY4Tpc44hSXO|YYm= MXq1NOKhdk1? M3HPelI1NTd{IHi= M2fjcYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhPDkEoHlCpC=> MW[yOlcxOjd6NB?=
HepG2 NUD3cHNrTnWwY4Tpc44hSXO|YYm= MoDmOVDDqG6P NES1T4IzPC15MjDo NGnkdY9qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|IHHmeIVzKDJ2wrDoxsA> NVLPVm9pOjZ5MEK3PFQ>
HCC827 NYHKcHpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq3OU84NjVxMUCgcm0> M3\iVFczyqCq MX\EUXNQ M2m4PIVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk MlHUNlY3PzV2OES=
A549  NYL0XIxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDqXXMyOC9zNT:yNEBvVQ>? MY[3NuKhcA>? NXfsc|h6TE2VTx?= M{jTVIVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk NUL6c5VlOjZ4N{W0PFQ>
NCI-H460  Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\HdVExNzJyL{OwJI5O MXu3NuKhcA>? NGPqXmZFVVOR M3nR[4VvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk NIPMdoYzPjZ5NUS4OC=>
J89GFP NWXLfXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D3fGROW00EoB?= M{Lle2VEPTB;NEmuPFUhyrFiMUKuOlUhdk1? NHPKbFkzPjV4M{W2PC=>
THP89GFP M17KZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfSbWNwTE2VT9Mg MV;FR|UxRTF7LkO0JOKyKDZwNEOgcm0> MYeyOlU3OzV4OB?=
SK-NEP-1 M3q1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfiV5ZlOC5yMfMAl|ExNjBizszN NIGwNnEzPCCq NUTtdoZZTE2VT9Mg MnzBTWM2OD15Nj6zOEBvVQ>? MnnQNlYyPzZ{MUm=
G401 M2LwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXu[2UxNjBz4pETNVAvOCEQvF2= MlX5NlQhcA>? M4\0WmROW00EoB?= NHe5dodKSzVyPUG0N{4xOiCwTR?= NHrKWnAzPjF5NkKxPS=>
SK-NEP-1 MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3;vNVUxKG6P M3n3WVHjiJN2IHS= M3Phb2ROW00EoB?= MUDy[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NHLoRnEzPjF5NkKxPS=>
G401 MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmSyOVAhdk1? MnX3NgKBmzRiZB?= MnraSG1UV8Li MVvy[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MlLwNlYyPzZ{MUm=
SK-NEP-1 MWnBdI9xfG:|aYOgRZN{[Xl? MWG1NE8yODBibl2= NYDrbpdiOjRiaB?= MnjzSG1UV8Li NV7zfJdMcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmnoNlYyPzZ{MUm=
G401 NXTCdoVOSXCxcITvd4l{KEG|c3H5 MlroOVAwOTByIH7N MXOyOEBp NELzRWVFVVORwrC= MkHtbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1;WdFI3OTd4MkG5
SK-NEP-1 M4noO2Z2dmO2aX;uJGF{e2G7 M{HkbVUxNzFyMDDuUS=> M3XvblI1KGh? M{KwdGROW00EoB?= MUDzbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v NWiwOI5pOjZzN{[yNVk>
G401 MYPGeY5kfGmxbjDBd5NigQ>? M4K2blUxNzFyMDDuUS=> NXPERlVvOjRiaB?= NXOwbIpRTE2VT9Mg NFO5SGx{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w M3WwVlI3OTd4MkG5
SK-NEP-1 NFnWTo9HfW6ldHnvckBCe3OjeR?= M4DTT|UxNzFyMDDuUS=> MkfzNlQhcA>? NFP5PFlFVVORwrC= NGTHOplqdmS3Y3XzJINmdGxiY4njcIUh\Gm|b4Lk[ZLDqA>? MoruNlYyPzZ{MUm=
G401 NIHhNZhHfW6ldHnvckBCe3OjeR?= M2HDNlUxNzFyMDDuUS=> NHvHPIUzPCCq NHywcXpFVVORwrC= Mn[1bY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA> NX7hNWY{OjZzN{[yNVk>
RPMI 8226 MX;D[YxtKFO3co\peoFtKEG|c3H5 NYXrXWp1Oi92L{[gcm0> NH3SXms1QOLCiXi= NVTKXIZicW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NYfHepBlOjZyMECyPVI>
OPM2 NFXQTHZE\WyuIGP1dpZqfmGuIFHzd4F6 M2[0SlIwPC94IH7N MYe0PQKBkWh? MXLpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp MVOyOlAxODJ7Mh?=
U266 NWD6[otzS2WubDDTeZJ3cX[jbDDBd5NigQ>? MkfFNk81NzZibl2= NEjN[Fc1QOLCiXi= NVu1RplVcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NUS5doZ1OjZyMECyPVI>
H929 M17jO2NmdGxiU4Xyeol3[WxiQYPzZZk> MmLENk81NzZibl2= NHTLZVg1QOLCiXi= MkTybY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? MWCyOlAxODJ7Mh?=
RPMI 8226  MYjBdI9xfG:|aYOgRZN{[Xl? M4XFXVTjiImwTR?= M17IfVI1NzR6IHi= NGLLUmxqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NVTCWINOOjZyMECyPVI>
HCC827 M{nmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2GyflExKG6P MUK0PEBp M2fBWmROW09? MXTlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>? M1Kxb|I2QTR2NkG3
NCI-H23 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\s[ZpuOTBibl2= Mkn1OFghcA>? NFm5Z3dFVVOR MoPS[Y5p[W6lZYOgZ4l{eGyjdHnuJJNmdnOrdHn2bZR6yqB? NH[zXXczPTl2NE[xOy=>
AML3 MV3GeY5kfGmxbjDBd5NigQ>? NET1cI0xNTFizszN NEC4NFQzPMLiaB?= NWLCOZZncW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFz2PVgzPTZzMkm0NS=>
ML-1 NHu3[XNHfW6ldHnvckBCe3OjeR?= M4f1fVAuOSEQvF2= NGLTVnMzPMLiaB?= M4jHXolv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mkm5NlU3OTJ7NEG=
RPMI-8226vr10  MUnGeY5kfGmxbjDBd5NigQ>? NEntR44xNTFizszN MonKNlTDqGh? MV7pcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXPGU2RbOjV4MUK5OFE>
ML-1 NXva[nV5TnWwY4Tpc44hSXO|YYm= MYWxJO69VQ>? NF3iU28zPMLiaB?= M3XSRolv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhPC2ob3zk MXOyOVYyOjl2MR?=
RPMI-8226vr10  NHfkfHJHfW6ldHnvckBCe3OjeR?= NID6dIMyKM7:TR?= M{nzSVI1yqCq NFjWe|ZqdmO{ZXHz[ZMh[2G|cHHz[U0{KGGldHn2bZR6KDJwNT3mc4xl NX;wZlB3OjV4MUK5OFE>
SK-N-BE (2) NF24WpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq3UFYzPOLCiXi= M4PoXmlEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= NIPaT3EzPTNyOEmxOi=>
SK-N-BE (2), PAN  MK M1X3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmyOQKBkWh? NWKwR2xbUUN3ME2xNFQvOOLCidMx5qCKPy56IH7N MnPJNlU{ODh7MU[=
SK-N-BE (2), MK  PAN NWLTW|d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LDWVI16oDLaB?= M4\tU2lEPTB;M{iyMlDjiIoEsfMAjVQ{NjJibl2= NFf6[pAzPTNyOEmxOi=>
SK-N-AS M1LIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7j[48zPOLCiXi= M2XERWlEPTB;M{euNgKBkcLz4pEJNk41KG6P NFi0VJYzPTNyOEmxOi=>
SK-N-DZ M1O0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuyOQKBkWh? NFrYdlJKSzVyPUG3MlHjiIoEsfMAjVAvPCCwTR?= M1HaeVI2OzB6OUG2
Caki-1 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxNE8zPS93MDDuUS=> NX76WmRlPDhiaB?= M2e4O4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= M4fHO|I2Ojd7MUmx
ACHN MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HDTlExNzJ3L{WwJI5O NXfNT|l5PDhiaB?= NF\BTnlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= NGK1d3gzPTJ5OUG5NS=>
769-P M1S2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGxNE8zPS93MDDuUS=> MojEOFghcA>? MlTVbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ NEjxTZUzPTJ5OUG5NS=>
786-O  NFT6fotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe0ZmcyOC9{NT:1NEBvVQ>? M4X2dFQ5KGh? NFjjN2tqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= M{\DT|I2Ojd7MUmx
Caki-1 NY\2fZRGSXCxcITvd4l{KEG|c3H5 M4nwWlUxKG6P NXvUUJRiPDhiaB?= NF\T[Y1qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= M2fWTVI2Ojd7MUmx
ACHN MVfBdI9xfG:|aYOgRZN{[Xl? MVW1NEBvVQ>? M1vIVlQ5KGh? MXnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? MVqyOVI4QTF7MR?=
769-P MWfBdI9xfG:|aYOgRZN{[Xl? NYryZVUyPTBibl2= MXy0PEBp NE\tU|FqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= M1nqdFI2Ojd7MUmx
786-O  NEDaZYVCeG:ydH;zbZMhSXO|YYm= M1LpZ|UxKG6P NHH0SZY1QCCq M2TEW4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ NVz0N5pqOjV{N{mxPVE>
Caki-1 NXjRO2V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3znZVI2NzVyIH7N MnvuOFghcA>? MljISG1UVw>? NIDhXZlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni NGDYdmIzPTF5NkO1OC=>
ACHN M4DYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUiyZ5RkOjVxNUCgcm0> NGezdmo1QCCq MkP4SG1UVw>? MUnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk MW[yOVE4PjN3NB?=
769-P NHjDZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX21U3c2OjVxNUCgcm0> NHSze|c1QCCq MYjEUXNQ MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk NHvsZoczPTF5NkO1OC=>
Caki-1 MknrR49td267IF\vdo1ifGmxbjDBd5NigQ>? MV:1NEBvVQ>? NWHRWGdNPy1zNDDk MoTLSG1UVw>? MlLnd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> NFPkUmIzPTF5NkO1OC=>
ACHN MmHQR49td267IF\vdo1ifGmxbjDBd5NigQ>? M1S1d|UxKG6P MnnMO{0yPCCm MlrOSG1UVw>? M4jiXpN2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh NWO0UnFqOjVzN{[zOVQ>
769-P M3;mOmNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? NIPxcIs2OCCwTR?= M3frdVcuOTRiZB?= MX3EUXNQ Mn3Pd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> MUOyOVE4PjN3NB?=
Caki-1 NXnjOWRNSXCxcITvd4l{KEG|c3H5 M2jWdFUxKG6P MmC2OFghcA>? NWDRTnBZTE2VTx?= NVnIUm1wcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NFPGTGIzPTF5NkO1OC=>
ACHN NH;5XVhCeG:ydH;zbZMhSXO|YYm= MoXOOVAhdk1? MV:0PEBp M2jrTWROW09? NULSdVgzcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NHvHb4YzPTF5NkO1OC=>
769-P NF7JXopCeG:ydH;zbZMhSXO|YYm= MlvaOVAhdk1? MX20PEBp MlLvSG1UVw>? NXH3fYJVcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M3jUdlI2OTd4M{W0
MDA-MB-231 MYXNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> MkDVNVDDqG6P NYHTfpVMO8LiZB?= MmH6SG1UVw>? Mni2ZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi NIfsd2kzPDhzMES5Oy=>
BT-549 MWDNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> MoLsNVDDqG6P MmLPN:Kh\A>? M1riXWROW09? MUPhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? NFnTe5IzPDhzMES5Oy=>
MCF-7  MmSwUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 NH3XeosyOMLibl2= M4LPNlPDqGR? M4fo[2ROW09? M3TFbIFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= MV[yOFgyODR7Nx?=
MCF-7 MYLGeY5kfGmxbjDBd5NigQ>? M4TPZlUuPTBibl2= NILKemEzPCCq NILFXXhFVVOR M13XdJJm\HWlZXSgeIhmKGyndnXsJI9nKGW6cILld5Nqd25ib3[gSXLPuSxiUGKgZY5lKE[xeFGxxsA> MVKyOFM3PjRyNx?=
CTS M{jZZWFxd3C2b4Ppd{BCe3OjeR?= MWCw5qCUPDBibl5CpC=> MoHoOFghcA>? NEXDOolqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVOyOFI1PDR{OR?=
OCI-AML3  M4Hkb2Fxd3C2b4Ppd{BCe3OjeR?= MmjnNQKBmzRyIH7NxsA> MkH0OFghcA>? NHS3[GpqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFXHbY8zPDJ2NESyPS=>
U937 NXmwN256SXCxcITvd4l{KEG|c3H5 NFnlRWox6oDVNECgcm3DqA>? MoTNOFghcA>? MlGxbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2XyelI1OjR2NEK5
PC3 NXTRboU2SXCxcITvd4l{KEG|c3H5 NI\YSYQxNTFyMDDuUS=> NEf2[XozPC92ODDo NXnmUFBvcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{m5XlI1OTZ|MkOw
PC3-AR NWHoVJhwSXCxcITvd4l{KEG|c3H5 NYjkSGdmOC1zMECgcm0> NWfuNo42OjRxNEigbC=> MmHXbY5lfWOnczDhdI9xfG:|aYOgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz NFqyPVAzPDF4M{KzNC=>
PC3 M{jOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTBeWExNTFyMDDuUS=> NFHmT2UzPC92ODDo MYjpcoR2[2W|IHHjZ5VufWyjdHnvckBw\iC|dXLHNUBxd3C3bHH0bY9v M1nMXlI1OTZ|MkOw
PC3-AR NXPsdWp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHPTnRzOC1zMECgcm0> M3fWPVI1NzR6IHi= Ml\nbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckB1cGViR{LNJJBp[XOn NG[0UYczPDF4M{KzNC=>
PC3 NUHkVVI2TnWwY4Tpc44hSXO|YYm= NYHDXmNkOC1zMECgcm0> M1vqXFI1KGh? NYPBfJQ3e3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4> NUn5NWtKOjRzNkOyN|A>
PC3-AR NYTETG5HTnWwY4Tpc44hSXO|YYm= NGPtXFcxNTFyMDDuUS=> MYWyOEBp MU\zeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= NVS0fFhlOjRzNkOyN|A>
OS-RC-2 NWnBZmFCS2WubDDWbYFjcWyrdImgRZN{[Xl? NF7MUYsxNTFyMECgcm0> MkGxNlQwPDhxN{KgbC=> NFy3N4pFVVOR MnHx[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MoXwNlQyPDR5M{e=
OS-RC-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;xdFUxKG6P MYC0PEBp MXvEUXNQ MYDpcoR2[2W|IFeyM20h[XK{ZYP0 M3HvdFI1OTR2N{O3
OS-RC-2 NInlOHFCeG:ydH;zbZMhSXO|YYm= NVLpOmpoPTBibl2= NIS3TGQ1QCCq M1mxemROW09? Mnq2bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NVf6UVhxOjRzNES3N|c>
SK-N-AS M2rvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\XdW9SOOLCk{iwJI5O MXW0PEBp MlHKTWM2OD1{Nz60JI5O M3PYR|I1ODl6N{m5
SK-N-DZ MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjwblVkOOLCk{iwJI5O NYP5NHhRPDhiaB?= Mm[4TWM2OD1{MT65JI5O MVyyOFA6QDd7OR?=
SK-N-SH MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe3UFEx6oDVOECgcm0> MVi0PEBp M4j1VWlEPTB;N{KuN{BvVQ>? MUGyOFA6QDd7OR?=
SK-N-BE Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGw5qCUQDBibl2= NETUVVE1QCCq NUTGSIJPUUN3ME23OU41KG6P MYiyOFA6QDd7OR?=
SK-N-AS MlvERZBweHSxc3nzJGF{e2G7 M4fk[lDjiJN6MDDuUS=> NW\5cJRxPDhiaB?= NH7aTmVxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> NF[5em8zPDB7OEe5PS=>
SK-N-DZ MVXBdI9xfG:|aYOgRZN{[Xl? MnXRNQKBmzhyIH7N M1PaeFQ5KGh? NHqxeWZxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> MUKyOFA6QDd7OR?=
SK-N-SH M37YVGFxd3C2b4Ppd{BCe3OjeR?= MkfoNQKBmzRyIH7N NFXzOWE1QCCq MmX3dI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u MkG3NlQxQTh5OUm=
SK-N-BE NH7KUJlCeG:ydH;zbZMhSXO|YYm= M3HHU|DjiJN2MDDuUS=> MlTROFghcA>? M1K0fJBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> NFrTV3UzPDB7OEe5PS=>
SK-N-AS NHfIfoVHfW6ldHnvckBCe3OjeR?= NGjvNHox6oDVOECgcm0> NHu5dZk1QCCq MmXBbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> NYf3ZnIyOjRyOUi3PVk>
SK-N-DZ M2DqbGZ2dmO2aX;uJGF{e2G7 NEexSnIx6oDVOECgcm0> MUm0PEBp M2PlT4lv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> MkHuNlQxQTh5OUm=
SK-N-SH NVnwSndzTnWwY4Tpc44hSXO|YYm= MWqw5qCUPDBibl2= NHXoU241QCCq M4rMXolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> MYmyOFA6QDd7OR?=
SK-N-BE M2DRTWZ2dmO2aX;uJGF{e2G7 NFHlfWwx6oDVNECgcm0> MkixOFghcA>? NUfz[G1{cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? M3O4bFI1ODl6N{m5
HCC-LM3 NXvhRm93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{CwNVEuOTByMDDuUS=> MYGyOE81QC95MjDo MmLWSG1UVw>? NUX3ZndZcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MYqyOFA6Ozl3Nh?=
HepG2 M{myNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PMbFEuOTByMDDuUS=> MljyNlQwPDhxN{KgbC=> NH[2fW1FVVOR NV\w[2tQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M{jSR|I1ODl|OUW2
SMMC-7721 MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7JcYsyOS1zMECwJI5O MoGzNlQwPDhxN{KgbC=> MoLwSG1UVw>? MX3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVeyOFA6Ozl3Nh?=
HCC-LM3 Mn3lRZBweHSxc3nzJGF{e2G7 NIK1VWo2OCCwTR?= M1WzZ|Q5KGh? M3\we2ROW09? NH3hW4pqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? MXKyOFA6Ozl3Nh?=
HepG2 MXrBdI9xfG:|aYOgRZN{[Xl? MYS1NEBvVQ>? MWe0PEBp M3ruZmROW09? MYXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgN{whQCCjbnSgPS=> NHi0Z|YzPDB7M{m1Oi=>
SMMC-7721 NW\LZYxCSXCxcITvd4l{KEG|c3H5 Ml7sOVAhdk1? M3Lp[VQ5KGh? NHKzeohFVVOR M2TRe4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 M3XsVlI1ODl|OUW2
HCC-LM3 MoizSpVv[3Srb36gRZN{[Xl? NGDTOHo2OC9zMECgcm0> MUmyOEBp MWnEUXNQ NILST5dl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg NH3wZXMzPDB7M{m1Oi=>
HepG2 NGqwVFhHfW6ldHnvckBCe3OjeR?= MXS1NE8yODBibl2= NV\JNpI4OjRiaB?= MkHUSG1UVw>? NEm5XZNl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg MXGyOFA6Ozl3Nh?=
SMMC-7721 NWCyTVV3TnWwY4Tpc44hSXO|YYm= MU[1NE8yODBibl2= MnLnNlQhcA>? M1vod2ROW09? NHnZR3dl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg MWSyOFA6Ozl3Nh?=
HCC-LM3 MnTNSpVv[3Srb36gRZN{[Xl? NX;JVoJXPTBxMUCwJI5O NHGwRWozPCCq NV\CbnFDTE2VTx?= Mnf0[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? MlqwNlQxQTN7NU[=
HepG2 MkLBSpVv[3Srb36gRZN{[Xl? M3HIS|UxNzFyMDDuUS=> M1rKNlI1KGh? M{LhVWROW09? NVHuPJpi\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= MWeyOFA6Ozl3Nh?=
SMMC-7721 MUHGeY5kfGmxbjDBd5NigQ>? NF3scG02OC9zMECgcm0> M1TZSFI1KGh? MWXEUXNQ NHnOVHFld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w NG\0c4IzPDB7M{m1Oi=>
FaDu M3;BNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV2xNFDjiIWwTR?= NV:4SFhSQC9zMD:xNkBp NX;CPWs1\Gm|cHzhfYVlKGFic3nncolncWOjboSgZY5lKHC{b3zvcodm\CCJMj;NJIFzemW|dDDheEA5KGGwZDCxNwKBjWhicH;zeEBz\WynYYPl NI\USZMzPDB{NkS4Ni=>
FaDu MlLiSpVv[3Srb36gRZN{[Xl? MWSxNFDjiIWwTR?= MlywNk81NzhxMUKgbC=> M2\xdolv\HWlZXSgdFIyX2GoMT;DbZAyyqCneIDy[ZN{cW:w NEjGdYUzPDB{NkS4Ni=>
PC-3  NXrMRVR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorENE0yOCEQvF2= MojWNlQwPDhxN{KgbC=> NU[zcGxqcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVGyN|k6OTJzNh?=
LNCaP MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV63cHNmOC13IN88US=> MW[yOE81QC95MjDo MkXtbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1XXNlI{QTlzMkG2
RWPE-1  MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnmNE0zOCEQvF2= MXmyOE81QC95MjDo NY\LfXZHcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWKyN|k6OTJzNh?=
Capan-1 NVG1WI1QTnWwY4Tpc44hSXO|YYm= Ml7mNlUwPTBxMUCwJI5O NGPMTIc5NzJ2L{S4JIg> NF7QZ|VFVVOR NYXEWolt\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> MmCxNlM6OjJ6OE[=
L3.6pl M4m2WWZ2dmO2aX;uJGF{e2G7 MXGyOU82OC9zMECgcm0> M2m5V|gwOjRxNEigbC=> NIfP[3dFVVOR Moq4[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= Mn3nNlM6OjJ6OE[=
CFPAC-1  NV\ESIVrTnWwY4Tpc44hSXO|YYm= M2fxblI2NzVyL{GwNEBvVQ>? NIT5cVI5NzJ2L{S4JIg> M3nC[mROW09? NXnpSYU3\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> MoX1NlM6OjJ6OE[=
Capan-1 M{LFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED5RpUzPS93MD:xNFAhdk1? MlXkOFghcA>? MV7EUXNQ MnT3doVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFPV[oEzOzl{Mki4Oi=>
L3.6pl NHfVXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj6PJgzPS93MD:xNFAhdk1? MYC0PEBp MXjEUXNQ MkHRdoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MlG5NlM6OjJ6OE[=
CFPAC-1  M3rHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXWTINiOjVxNUCvNVAxKG6P NW[xWZpYPDhiaB?= NXXzNmdqTE2VTx?= MnvNdoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mn7vNlM6OjJ6OE[=
Capan-1 NXXBU5RuSXCxcITvd4l{KEG|c3H5 NUXoUnB5OjVxNUCvNVAxKG6P NXrCWXNOPDhiaB?= NXywW3FwTE2VTx?= M3q5T4lv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVKyN|kzOjh6Nh?=
L3.6pl MX;BdI9xfG:|aYOgRZN{[Xl? NHLtbYYzPS93MD:xNFAhdk1? MmHEOFghcA>? NWC2ZpVMTE2VTx?= MmLVbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M17Re|I{QTJ{OEi2
CFPAC-1  M4e5[WFxd3C2b4Ppd{BCe3OjeR?= NWLmcZZVOjVxNUCvNVAxKG6P NIjHU481QCCq NVXzRll3TE2VTx?= NV3PNlBicW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2jkZVI{QTJ{OEi2
HN22 MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rtbFAuOjBibl2= MYiyOE81QCCq NE[1Z2FFVVOR NWLrcoZmcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? NXvse4gzOjN6N{eyN|U>
HSC4  M1\4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuwMVIxKG6P NHvVN3kzPC92ODDo M2XjPGROW09? MXnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy NVnwboZMOjN6N{eyN|U>
HN22 NYj3OVZySXCxcITvd4l{KEG|c3H5 MVOwMVIxKG6P MXe0PEBp M2\TdmROW09? NVfPSmR[cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NFrwU4YzOzh5N{KzOS=>
HSC4  Ml7oRZBweHSxc3nzJGF{e2G7 M1XPeFAuOjBibl2= NHfhSI41QCCq MlvNSG1UVw>? NX:2N5c4cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NE\Wc4ozOzh5N{KzOS=>
HN22 Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\JR2oxNTJyIH7N NYPV[XZDPDhiaB?= NH7KTlVFVVOR M{X1O4lv\HWlZYOgS|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=> MoLkNlM5Pzd{M{W=
HSC4  NH\1SJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnSR2JCOC1{MDDuUS=> Moq3OFghcA>? Mn2xSG1UVw>? NFjDOWpqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA> Ml7PNlM5Pzd{M{W=
HN22 MXfGeY5kfGmxbjDBd5NigQ>? MUCwMVIxKG6P NWjSOoV3PDhiaB?= NHTDSVhFVVOR MnTMd5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg MmLoNlM5Pzd{M{W=
HSC4  M2jnSmZ2dmO2aX;uJGF{e2G7 MoTQNE0zOCCwTR?= M{TiSVQ5KGh? NVH5O4xsTE2VTx?= Ml;yd5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg NX33eZUyOjN6N{eyN|U>
Cal62 NUntPZFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTN|INMxJFQhdk1? MnPyNlM5OjRyNkS=
Hth7 NFTOUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHCfWRKSzVyPUG1JOKyKDJibl2= MY[yN|gzPDB4NB?=
Hth83 NFzUbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTN2INMxJFUhdk1? MmnjNlM5OjRyNkS=
C643 NYP3ToJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTdzINMxJFExKG6P MXSyN|gzPDB4NB?=
SW1736 NF\JOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\RNmlEPTB;M{WgxtEhQCCwTR?= MYWyN|gzPDB4NB?=
T241 NEDJOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnRTWM2OD14NTFCtUA4KG6P M4DadFI{QDJ2ME[0
T351 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTVyINMxJFExKG6P M3PKd|I{QDJ2ME[0
BHP2-7 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTN5INMxJFYhdk1? MkT0NlM5OjRyNkS=
T238 NXvxWXlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TCVGlEPTB;MTy1NFAhyrFiMkCwJI5O NF7YRWozOzh{NEC2OC=>
HCT8 M{XwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HaeVczKGh? NGDYR5dFVVOR MnvtTWM2OD1zMj655qCKyrIkgJmxMlkhdk1? MYmyN|I6QTN6OB?=
H630 NGfhXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrTSJhXPzJiaB?= M3n4b2ROW09? MX\JR|UxRTF{LkVihKnDueLCiUOuNUBvVQ>? M4DJ[VI{Ojl7M{i4
cH630 5-FU-res NULxbnZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH6T3U4OiCq Ml3TSG1UVw>? NE\zWFlKSzVyPUG1MlXjiIoEsfMAjVEvOiCwTR?= NFr4dWkzOzJ7OUO4PC=>
HCT116 M1nJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPHO|IhcA>? NYPtUmlHTE2VTx?= MUPJR|UxRTFyLkhihKnDueLCiUKuNkBvVQ>? M3HQTFI{Ojl7M{i4
HCT116 p53−/− M{Thcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXW3NkBp MWHEUXNQ MWnJR|UxRThwNvMAjeKy6oDLMT63JI5O M2rmXVI{Ojl7M{i4
dHCT116 p21−/− NEf3PWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm3VoZCPzJiaB?= MUHEUXNQ M1fxXmlEPTB;NT655qCKyrIkgJmxMlMhdk1? MlnRNlMzQTl|OEi=
HT29 M1Sw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVv6c2VVPzJiaB?= NW\qSXRJTE2VTx?= M3voRmlEPTB;MU[uN-KBkcLz4pEJNk4{KG6P NYLkT2NbOjN{OUmzPFg>
LoVo NXK5dHhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv1O|IhcA>? NV\6WGprTE2VTx?= Mk\QTWM2OD13LkJihKnDueLCiUCuOkBvVQ>? MXqyN|I6QTN6OB?=
RKO M2DWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIKydm04OiCq NYPTOnBqTE2VTx?= NYfsWFd5UUN3ME23MlnjiIoEsfMAjVIvOiCwTR?= MoW0NlMzQTl|OEi=
SW480 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUK3NkBp M3fqWmROW09? MofnTWM2OD1zNz615qCKyrIkgJmwMlghdk1? NVm5eHFTOjN{OUmzPFg>
eSW620 NFXDZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DHTFczKGh? MmfSSG1UVw>? M3PKO2lEPTB;OT6x5qCKyrIkgJmyMlEhdk1? MV2yN|I6QTN6OB?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589
Smiles CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=C([NH]1)C=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04341311 Not yet recruiting Drug: Marizomib|Drug: Panobinostat Diffuse Intrinsic Pontine Glioma|Pediatric Brainstem Glioma|Pediatric Brainstem Gliosarcoma Recurrent|Pediatric Cancer|Pediatric Brain Tumor|Diffuse Glioma Dana-Farber Cancer Institute|Celgene|Secura Bio May 2020 Phase 1
NCT03632317 Withdrawn Drug: Panobinostat|Drug: Everolimus Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center October 2019 Phase 2
NCT03982134 Withdrawn Drug: PDR001|Drug: Panobinostat Melanoma|Non Small Cell Lung Cancer Muhammad Furqan|Novartis Pharmaceuticals|University of Iowa September 2019 Phase 1
NCT04326764 Recruiting Drug: Panobinostat Acute Myeloid Leukaemia (AML)|Myelodysplastic Syndromes (MDS) Goethe University|Jan J. Cornelissen (HOVON-SAKK)|Sebastian Giebel (PALG) July 24 2018 Phase 3
NCT03515915 Unknown status -- Patients With Recurrent or Refractory Multiple Myeloma University Hospital Montpellier|Poitiers University Hospital April 23 2018 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID